Advertisement
ABBV or BMY or PRAX
Which Stock Would AI Choose? AbbVie (ABBV) vs. Bristol-Myers Squibb (BMY) vs. Praxis Precision Medicines (PRAX) Stock Comparison
Key Takeaways
- ABBV (~$227, $401B market cap) delivers stable performance with YTD gains around 0.15% and strong revenue of $61B, driven by immunology and oncology pipeline advancements in recent weeks.
- BMY (~$60, $122B market cap) leads YTD with ~13% gains, bolstered by positive Phase III data for mezigdomide and expansions like Sotyktu, trading at a lower P/E of ~17x.
- PRAX (~$310, $8.6B market cap) shows explosive 1-year growth over 700%, fueled by NDA filings for CNS therapies, though pre-revenue with high volatility (beta 3.01).
- Established players ABBV and BMY offer profitability and dividends (3-4% yields), contrasting PRAX's high-risk, high-reward biotech profile.
- Recent momentum favors BMY amid pipeline wins, while PRAX dominates relative performance but carries greater execution risks.
- Valuation sensitivity: BMY appears most attractive at forward P/E ~10x versus ABBV's 16x and PRAX's N/A.
Introduction
This stock comparison examines ABBV, BMY, and PRAX, three biopharma names spanning large-cap stalwarts to clinical-stage biotech. ABBV and BMY represent established players with diversified portfolios in immunology, oncology, and beyond, while PRAX targets CNS disorders via precision therapies. Investors seeking income and stability may favor the giants, whereas growth-oriented traders eye PRAX's momentum. Recent market activity highlights pipeline catalysts and relative performance, aiding decisions on sector exposure, valuation sensitivity, and risk trade-offs in the current environment.
ABBV Overview and Recent Performance
AbbVie Inc. (ABBV) is a research-based biopharmaceutical leader focused on immunology, oncology, neuroscience, and aesthetics, with flagships like Skyrizi, Rinvoq, and Botox. Trading near $227 with a $401 billion market cap, the stock has shown resilience in recent market activity, posting modest YTD gains of about 0.15% amid broader pharma volatility. Influences include positive topline results from Phase 1 studies like ABBV-295 for obesity and strong growth projections for immunology assets, offsetting Humira erosion. Revenue reached $61 billion TTM, with EPS at $2.36 and a P/E of 96x reflecting premium valuation. Sentiment benefits from $380 million U.S. manufacturing expansion and oncology advancements like Elahere, supporting trend consistency despite weekly dips of ~2-3%.
BMY Overview and Recent Performance
Bristol-Myers Squibb (BMY) develops biopharma products in oncology, immunology, and cardiovascular areas, featuring Opdivo, Eliquis, and newer entrants like Sotyktu. At around $60 with a $122 billion market cap, shares have outperformed YTD by ~13%, with monthly gains near 1% amid sector pressures. Key drivers include positive Phase III results for mezigdomide in blood cancer and FDA approval expansions for Sotyktu in psoriatic arthritis, alongside UBS raising its price target to $70. TTM revenue stands at $48 billion, EPS $3.46, and P/E ~17x signaling value. Recent momentum from growth portfolio strength has lifted sentiment, though weekly declines of ~3% reflect broader market caution.
PRAX Overview and Recent Performance
Praxis Precision Medicines, Inc. (PRAX) is a clinical-stage biotech advancing therapies for CNS disorders like epilepsy and essential tremor via small-molecule and ASO platforms, including ulixacaltamide and relutrigine. Shares hover near $310 with an $8.6 billion market cap, delivering explosive 1-year returns over 700% and YTD ~5%, far outpacing peers. Catalysts encompass dual NDA submissions with Breakthrough Therapy designations and Phase 3 progress, backed by $926 million cash into 2028 post-financing. Pre-revenue with EPS -$13.48, high beta (3.01) amplifies volatility—recent weeks saw ~5% drops despite surges. Investor buys like $81 million underscore sentiment shifts toward pipeline potential.
Trending AI Robots
Tickeron’s Trending AI Robots page curates the platform's top-performing AI trading bots from hundreds available, which collectively trade thousands of tickers across diverse strategies, timeframes, and sectors like biotech, pharma, semiconductors, and ETFs. Only those excelling in current conditions—such as short-term momentum or volatility plays—earn a spot, with over 25 featured boasting annualized returns from +14% to +216%, win rates of 53-95%, and profit factors up to 25.8. Examples include a volatility bot at +216% annualized (76% win rate) on 3 tickers and a multi-sector agent at +133% (62% win rate, 2.7 profit factor). These vary from 15min scalps to multi-day holds, often outperforming the S&P 500. Explore Trending AI Robots to identify suitable options for real-time signals and copy trading.
Head-to-Head Comparison
ABBV and BMY share large-cap pharma models with broad pipelines and revenue streams ($61B vs. $48B), contrasting PRAX's focused CNS biotech without profits. Growth drivers differ: ABBV's immunology/neuroscience stability vs. BMY's oncology expansions and PRAX's NDA catalysts. Recent momentum favors BMY (13% YTD) over ABBV (0.15%) and PRAX (5% YTD, but 700% 1Y). Risks: Patent cliffs for giants, clinical failures for PRAX (beta 3x higher). Sector exposure aligns in biopharma, but PRAX amplifies biotech volatility. Valuation: BMY cheapest (P/E 17x forward 10x), ABBV premium (96x), PRAX speculative. Sentiment tilts to BMY value and PRAX upside.
Tickeron AI Verdict
Tickeron’s AI currently leans toward BMY based on superior recent momentum (13% YTD), attractive valuation (forward P/E ~10x), pipeline catalysts like Phase III wins, and relative stability versus peers. While PRAX offers trend consistency via explosive growth and ABBV provides defensive positioning, BMY's profit factor and lower risk profile suggest higher probability of outperformance in the near term amid biopharma rotations.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer. Disclaimers and Limitations
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
ABBV’s FA Score shows that 2 FA rating(s) are green whileBMY’s FA Score has 2 green FA rating(s), and PRAX’s FA Score reflects 0 green FA rating(s).
- ABBV’s FA Score: 2 green, 3 red.
- BMY’s FA Score: 2 green, 3 red.
- PRAX’s FA Score: 0 green, 5 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
ABBV’s TA Score shows that 6 TA indicator(s) are bullish while BMY’s TA Score has 6 bullish TA indicator(s), and PRAX’s TA Score reflects 5 bullish TA indicator(s).
- ABBV’s TA Score: 6 bullish, 4 bearish.
- BMY’s TA Score: 6 bullish, 4 bearish.
- PRAX’s TA Score: 5 bullish, 4 bearish.
Price Growth
ABBV (@Pharmaceuticals: Major) experienced а +1.04% price change this week, while BMY (@Pharmaceuticals: Major) price change was +2.64% , and PRAX (@Biotechnology) price fluctuated +8.34% for the same time period.
The average weekly price growth across all stocks in the @Pharmaceuticals: Major industry was +1.21%. For the same industry, the average monthly price growth was +2.48%, and the average quarterly price growth was +7.89%.
The average weekly price growth across all stocks in the @Biotechnology industry was +7.61%. For the same industry, the average monthly price growth was +9.02%, and the average quarterly price growth was +11.47%.
Reported Earning Dates
ABBV is expected to report earnings on Apr 29, 2026.
BMY is expected to report earnings on Apr 30, 2026.
PRAX is expected to report earnings on May 13, 2026.
Industries' Descriptions
@Pharmaceuticals: Major (+1.21% weekly)The Major Pharmaceuticals industry includes companies that are involved in various processes of creating drugs to treat/prevent diseases. These companies engage in research, testing and manufacturing, as well as the distribution of pharmaceuticals into markets. Johnson & Johnson, Merck & Co., Inc., Pfizer Inc. and Novartis are among the largest companies in this category.
@Biotechnology (+7.61% weekly)Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
| ABBV | BMY | PRAX | |
| Capitalization | 369B | 123B | 9.54B |
| EBITDA | 17.6B | 15.2B | -326.06M |
| Gain YTD | -7.305 | 14.032 | 16.204 |
| P/E Ratio | 87.92 | 17.39 | N/A |
| Revenue | 61.2B | 48.2B | 0 |
| Total Cash | N/A | N/A | 599M |
| Total Debt | 67.5B | 47.1B | 110K |
ABBV | BMY | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 60 | 9 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 35 Fair valued | 41 Fair valued | |
PROFIT vs RISK RATING 1..100 | 14 | 81 | |
SMR RATING 1..100 | 1 | 23 | |
PRICE GROWTH RATING 1..100 | 55 | 21 | |
P/E GROWTH RATING 1..100 | 40 | 66 | |
SEASONALITY SCORE 1..100 | n/a | n/a |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
ABBV's Valuation (35) in the Pharmaceuticals Major industry is in the same range as BMY (41). This means that ABBV’s stock grew similarly to BMY’s over the last 12 months.
ABBV's Profit vs Risk Rating (14) in the Pharmaceuticals Major industry is significantly better than the same rating for BMY (81). This means that ABBV’s stock grew significantly faster than BMY’s over the last 12 months.
ABBV's SMR Rating (1) in the Pharmaceuticals Major industry is in the same range as BMY (23). This means that ABBV’s stock grew similarly to BMY’s over the last 12 months.
BMY's Price Growth Rating (21) in the Pharmaceuticals Major industry is somewhat better than the same rating for ABBV (55). This means that BMY’s stock grew somewhat faster than ABBV’s over the last 12 months.
ABBV's P/E Growth Rating (40) in the Pharmaceuticals Major industry is in the same range as BMY (66). This means that ABBV’s stock grew similarly to BMY’s over the last 12 months.
| ABBV | BMY | PRAX | |
|---|---|---|---|
| RSI ODDS (%) | 3 days ago 63% | 3 days ago 42% | N/A |
| Stochastic ODDS (%) | 3 days ago 58% | 3 days ago 48% | 3 days ago 90% |
| Momentum ODDS (%) | 3 days ago 65% | 3 days ago 45% | 3 days ago 90% |
| MACD ODDS (%) | 3 days ago 67% | 3 days ago 55% | 3 days ago 90% |
| TrendWeek ODDS (%) | 3 days ago 58% | 3 days ago 52% | 3 days ago 86% |
| TrendMonth ODDS (%) | 3 days ago 51% | 3 days ago 54% | 3 days ago 88% |
| Advances ODDS (%) | 11 days ago 57% | 3 days ago 54% | 6 days ago 84% |
| Declines ODDS (%) | 7 days ago 48% | 7 days ago 53% | 4 days ago 84% |
| BollingerBands ODDS (%) | 3 days ago 62% | 3 days ago 48% | 3 days ago 86% |
| Aroon ODDS (%) | 3 days ago 43% | 3 days ago 55% | 3 days ago 86% |
Advertisement
| 1 Day | |||
|---|---|---|---|
| ETFs / NAME | Price $ | Chg $ | Chg % |
| NETG | 10.89 | 0.34 | +3.26% |
| Leverage Shares 2X Long NET Daily ETF | |||
| HELX | 34.83 | 0.81 | +2.38% |
| Franklin Genomic Advancements ETF | |||
| FYT | 66.55 | 1.46 | +2.24% |
| First Trust Small Cap Val AlphaDEX® ETF | |||
| IJR | 135.39 | 2.70 | +2.03% |
| iShares Core S&P Small-Cap ETF | |||
| ULTY | 32.21 | 0.50 | +1.58% |
| YieldMax Ultra Option Income Strat ETF | |||
ABBV and
Correlation & Price change
A.I.dvisor indicates that over the last year, ABBV has been loosely correlated with PFE. These tickers have moved in lockstep 57% of the time. This A.I.-generated data suggests there is some statistical probability that if ABBV jumps, then PFE could also see price increases.
| Ticker / NAME | Correlation To ABBV | 1D Price Change % | ||
|---|---|---|---|---|
| ABBV | 100% | -0.29% | ||
| PFE - ABBV | 57% Loosely correlated | +1.25% | ||
| BMY - ABBV | 55% Loosely correlated | +2.05% | ||
| BIIB - ABBV | 51% Loosely correlated | +0.76% | ||
| AMGN - ABBV | 51% Loosely correlated | +1.69% | ||
| NVS - ABBV | 49% Loosely correlated | +1.50% | ||
More | ||||
PRAX and
Correlation & Price change
A.I.dvisor indicates that over the last year, PRAX has been loosely correlated with BEAM. These tickers have moved in lockstep 40% of the time. This A.I.-generated data suggests there is some statistical probability that if PRAX jumps, then BEAM could also see price increases.
| Ticker / NAME | Correlation To PRAX | 1D Price Change % | ||
|---|---|---|---|---|
| PRAX | 100% | +6.90% | ||
| BEAM - PRAX | 40% Loosely correlated | +3.49% | ||
| BHVN - PRAX | 37% Loosely correlated | +9.69% | ||
| RAPP - PRAX | 35% Loosely correlated | +0.43% | ||
| VERU - PRAX | 35% Loosely correlated | -1.21% | ||
| RXRX - PRAX | 35% Loosely correlated | +5.00% | ||
More | ||||